Literature DB >> 25433744

Exciting directions in glaucoma.

Carol A Rasmussen1, Paul L Kaufman2.   

Abstract

Glaucoma is a complex, life-long disease that requires an individualized, multifaceted approach to treatment. Most patients will be started on topical ocular hypotensive eyedrop therapy, and over time multiple classes of drugs will be needed to control their intraocular pressure. The search for drugs with novel mechanisms of action, to treat those who do not achieve adequate intraocular pressure control with, or become refractory to, current therapeutics, is ongoing, as is the search for more efficient, targeted drug delivery methods. Gene-transfer and stem-cell applications for glaucoma therapeutics are moving forward. Advances in imaging technologies improve our understanding of glaucoma pathophysiology and enable more refined patient evaluation and monitoring, improving patient outcomes.
Copyright © 2014 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25433744      PMCID: PMC4250930          DOI: 10.1016/j.jcjo.2014.08.007

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  110 in total

1.  Effects of latrunculin-B on outflow facility and trabecular meshwork structure in human eyes.

Authors:  C Ross Ethier; A Thomas Read; Darren W-H Chan
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

Review 2.  A tissue-engineered approach towards retinal repair: scaffolds for cell transplantation to the subretinal space.

Authors:  Sara Royce Hynes; Erin B Lavik
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-19       Impact factor: 3.117

Review 3.  Benzalkonium chloride and glaucoma.

Authors:  Carol A Rasmussen; Paul L Kaufman; Julie A Kiland
Journal:  J Ocul Pharmacol Ther       Date:  2013-11-08       Impact factor: 2.671

4.  Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers.

Authors:  Casey Kopczynski; Gary D Novack; Dennis Swearingen; Thomas van Haarlem
Journal:  Br J Ophthalmol       Date:  2013-02-22       Impact factor: 4.638

5.  Effects of the marine macrolides swinholide A and jasplakinolide on outflow facility in monkeys.

Authors:  B Tian; J A Kiland; P L Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-12       Impact factor: 4.799

6.  The role of the prostaglandin EP4 receptor in the regulation of human outflow facility.

Authors:  Lindsay H Millard; David F Woodward; W Daniel Stamer
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-01       Impact factor: 4.799

7.  Atrophy of the lateral geniculate nucleus in human glaucoma detected by magnetic resonance imaging.

Authors:  N Gupta; G Greenberg; L Noël de Tilly; B Gray; M Polemidiotis; Y H Yücel
Journal:  Br J Ophthalmol       Date:  2008-08-12       Impact factor: 4.638

Review 8.  Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma.

Authors:  Yeni H Yücel; Qiang Zhang; Robert N Weinreb; Paul L Kaufman; Neeru Gupta
Journal:  Prog Retin Eye Res       Date:  2003-07       Impact factor: 21.198

9.  AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia.

Authors:  Sarah Van de Velde; Tine Van Bergen; Davine Sijnave; Karolien Hollanders; Karolien Castermans; Olivier Defert; Dirk Leysen; Evelien Vandewalle; Lieve Moons; Ingeborg Stalmans
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-18       Impact factor: 4.799

10.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.

Authors:  Robert E MacLaren; Markus Groppe; Alun R Barnard; Charles L Cottriall; Tanya Tolmachova; Len Seymour; K Reed Clark; Matthew J During; Frans P M Cremers; Graeme C M Black; Andrew J Lotery; Susan M Downes; Andrew R Webster; Miguel C Seabra
Journal:  Lancet       Date:  2014-01-16       Impact factor: 79.321

View more
  7 in total

Review 1.  Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.

Authors:  Paul L Kaufman
Journal:  Expert Opin Pharmacother       Date:  2017-02-20       Impact factor: 3.889

2.  Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents.

Authors:  Uttio Roy Chowdhury; Tommy A Rinkoski; Cindy K Bahler; J Cameron Millar; Jacques A Bertrand; Bradley H Holman; Joseph M Sherwood; Darryl R Overby; Kristen L Stoltz; Peter I Dosa; Michael P Fautsch
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-11-01       Impact factor: 4.799

3.  Biomechanical, ultrastructural, and electrophysiological characterization of the non-human primate experimental glaucoma model.

Authors:  VijayKrishna Raghunathan; J Seth Eaton; Brian J Christian; Joshua T Morgan; James N Ver Hoeve; Chen-Yuan Charlie Yang; Haiyan Gong; Carol A Rasmussen; Paul E Miller; Paul Russell; T Michael Nork; Christopher J Murphy
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

4.  ATP-sensitive potassium (KATP) channel openers diazoxide and nicorandil lower intraocular pressure by activating the Erk1/2 signaling pathway.

Authors:  Uttio Roy Chowdhury; Cindy K Bahler; Bradley H Holman; Michael P Fautsch
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

5.  Ocular Hypotensive Effects of the ATP-Sensitive Potassium Channel Opener Cromakalim in Human and Murine Experimental Model Systems.

Authors:  Uttio Roy Chowdhury; Cindy K Bahler; Bradley H Holman; Peter I Dosa; Michael P Fautsch
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

6.  Proteasome Inhibition Increases the Efficiency of Lentiviral Vector-Mediated Transduction of Trabecular Meshwork.

Authors:  Zeynep Aktas; Hongyu Rao; Sarah R Slauson; B'Ann T Gabelt; Inna V Larsen; Rachael T C Sheridan; Leonie Herrnberger; Ernst R Tamm; Paul L Kaufman; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-01-01       Impact factor: 4.799

Review 7.  Neurodegeneration and Neuroprotection in Glaucoma.

Authors:  Angela C Gauthier; Ji Liu
Journal:  Yale J Biol Med       Date:  2016-03-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.